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Abstract
Gamma-hydroxybutyric acid (GHB) is an endogenous brain substance that has diverse neuropharmaco-
logical actions, including rewarding properties in diﬀerent animal species and in humans. As other drugs
of abuse, GHB aﬀects the ﬁring of ventral tegmental neurons (VTA) in anaesthetized animals and hy-
perpolarizes dopaminergic neurons in VTA slices. However, no direct behavioural data on the eﬀects of
GHB applied in the VTA or in the target regions of its dopaminergic neurons, e.g. the nucleus accumbens
(NAc), are available. Here, we investigated the eﬀects of various doses of intravenous GHB in maintaining
self-administration (from 0.001 to 10 mg/kg per infusion), and its ability to induce conditioned place
preference (CPP) in rats when given orally (175–350 mg/kg) or injected directly either in the VTA or NAc
(from 10 to 300 mg/0.5 ml per side). Our results indicate that while only 0.01 mg/kg per infusion GHB
maintained self-administration, although not on every test day, 350 mg/kg GHB given orally induced
CPP. CPP was also observed when GHB was injected in the VTA (30–100 mg/0.5 ml per side) but not in the
NAc. Together with recent in-vitro ﬁndings, these results suggest that the rewarding properties of GHB
mainly occur via disinhibition of VTA dopaminergic neurons.
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Introduction
Gamma-hydroxybutyric acid (GHB) is generated in
mammalian brains from the metabolism of gamma-
aminobutyric acid (GABA) (Crunelli et al. 2006 ;
Maitre, 1997 ; Wong et al. 2004). Although GHB may
act as a neurotransmitter (Bernasconi et al. 1999; Cash,
1994) or as a source of neuronal GABA (Chambliss
& Gibson, 1992), a full understanding of its physio-
logical role(s) remains unclear. GHB has diverse
neuropharmacological properties, including activa-
tion of both GABAB receptors (Lingenhoehl et al. 1999;
Mathivet et al. 1997), and putative GHB receptors
(Maitre, 1997 ; but see Crunelli et al. 2006).
Exogenously administered GHB elicits sedation,
memory loss, euphoria, behavioural disinhibition and
sleep (Abanades et al. 2007 ; Carter et al. 2006 ; Laborit,
1960 ; Miotto et al. 2001 ; Wong et al. 2004). GHB has
found clinical use in the treatment of alcohol and opiate
withdrawal and in promoting long-term abstinence
from these drugs (Addolorato et al. 1999 ; Caputo et al.
2005 ; Gallimberti et al. 1989 ; Nava et al. 2007), whereas
its use as an anaesthetic induction agent has now
been discontinued (Kam & Yoong, 1998). More re-
cently, GHB has been prescribed for the treatment of
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narcolepsy and cataplexy (Black & Guilleminault,
2001 ; Pardi & Black, 2006 ; Tunnicliﬀ & Raess, 2002).
GHB emerged as a recreational drug in the 1970s
and remains one of the commonly used ‘club drugs’
(Degenhardt et al. 2005 ; Ricaurte & McCann, 2005;
Snead & Gibson, 2005 ; Sumnall et al. 2008), with acci-
dental overdoses that occur in recreational nightlife
settings accounting for a substantial proportion of
the overall hospital emergencies, at least in Europe
(EMCDDA, 2008).
To unravel the mechanism underlying the reinfor-
cing properties of GHB, several studies investigated its
eﬀects in various species, but the results are inconclus-
ive. Thus, GHB is not intravenously self-administered
by monkeys experienced in the self-administration of
phencyclidine or methohexital (Beardsley et al. 1996;
Woolverton et al. 1999), but is intravenously self-
administered by naive mice (Fattore et al. 2001;
Martellotta et al. 1998), although only data from the
ﬁrst day of self-administration were reported in the
latter studies. Orally, GHB is self-administered by
mice and rats (Colombo et al. 1995 ; Laboue`be et al.
2007), although in the latter species periods of volun-
tary abstinence were observed and self-administration
was often irregular. Oral GHB can induce conditioned
place preference (CPP) in rats (Martellotta et al. 1997)
and mice (Itzhak & Syed, 2002).
The involvement of mesocorticolimbic dopaminer-
gic systems in reward-dependent learning of addictive
drugs is well known (Fibiger & Phillips, 1988 ; Lu¨scher
& Ungless, 2006). Drugs of abuse directly or indirectly
activate ascending dopaminergic neurons in the ven-
tral tegmental area (VTA), elevating dopamine levels
at their site of termination in the nucleus accumbens
(NAc) and prefrontal cortex (Di Chiara & Imperato,
1988 ; Koob, 1992). GHB too has been shown to target
the mesolimbic system in vivo, leading to a moderate
stimulation of the dopaminergic system (Pistis et al.
2005). In vitro, low concentration of GHB preferentially
inhibits VTA GABAergic neurons, with a resulting
disinhibition of dopaminergic neurons, leading to an
increased VTA output that would underlie GHB’s re-
warding properties (Cruz et al. 2004 ; Laboue`be et al.
2007).
However, no direct behavioural data are available
on the role of the NAc and/or VTA in the rewarding
properties of GHB. Thus, here we ﬁrst investigated its
ability to maintain self-administration and to induce
CPP in rats, and later assessed whether these eﬀects
could be reproduced by GHB injected directly into
the VTA or the NAc. Our results demonstrate that
GHB, while unable to reliably maintain intravenous
self-administration, induces CPP when administered
orally or when injected in the VTA but not in the NAc.
A preliminary report of some of these results has been
published (Watson et al. 2007).
Material and methods
Animal procedures were conducted in conformity
with institutional guidelines, and national (D.L. 116)
and international policies (EEC Directive 86/609;
Guide for the Care and Use of Laboratory Animals,
USA). Male Wistar rats (Charles River, Italy), weigh-
ing 175–200 g, were housed individually in the self-
administration studies, or two per cage in the CPP
experiments, at constant room temperature (21¡1 xC)
and relative humidity (60%) under a 12-h light/dark
cycle (lights on 07:30 hours) with food and water
available ad libitum. Animals were allowed to adapt to
the laboratory conditions for at least 1 wk before ex-
periments commenced, and were handled daily dur-
ing this period.
Self-administration studies
Apparatus
Animals were trained and tested using eight standard
rodent operant test chambers (ENV-007, Med Associ-
ates Inc., USA) equipped with two retractable levers
and three lights, each 2.8 W, 24 V, one in the middle
back of the ceiling, and two on the front panel 6 cm
above each lever. In four chambers the right-hand
lever was designated as the active lever, in the other
chambers it was the left-hand one. Each chamber
was installed inside a sound-attenuating cubicle, with
an exhaust fan mounted on one side. Intravenous
infusions were administered via a syringe pump
(PHM-100, Med Associates Inc.) located inside the
sound-attenuating cubicles. Stimulus lights, pellet dis-
penser, and syringe pump were controlled by a com-
puter running the Med Associates software.
Experimental procedures
In the ﬁrst series of experiments, the training and
testing was conducted during the light phase of the
light/dark cycle, starting at 09:00 hours. To facilitate
the acquisition of GHB self-administration, rats were
initially trained to press a lever for food pellets on a
ﬁxed ratio 2 (FR2) schedule. During this period and
throughout these experiments, the animals were
placed on a restricted diet (20 g/d rat chow) (Altromin
MT, Rieper, Italy), suﬃcient to maintain body weight
and growth. The ﬁrst session consisted of 30 min of
non-contingent delivery of one 45-mg food pellet
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(Noyes improved formula A/I, Sandown Scientiﬁc,
UK) every 30 s. In addition, each lever press delivered
one food pellet. From the second 30-min session, food
pellets were available on a FR1 schedule with only the
active lever being available. From the third session, the
FR was increased to 2 and the second inactive lever
was introduced. Animals received a minimum of three
30-min food-training sessions under FR2 in which they
earned 100 pellets.
At the end of this training (6–7 d), rats were anaes-
thetized (equithesin 3.0 ml/kg i.p.) and implanted
in the right jugular vein with a catheter as previously
described (Cervo et al. 2003). During the 5-d recovery
period, rats received one daily subcutaneous (s.c.) in-
jection of 45 mg/kg ampicillin (Amplital1, Pharmacia,
Italy). Catheters were kept patent by daily intra-
venous infusions of 0.1 ml heparinized (30 U/ml,
Opocrin S.p.A., Italy) sterile saline before and after
each self-administration session. At the end of the
self-administration period, patency was veriﬁed by
intravenously injecting 0.05 ml of 1.25 mg/ml mid-
azolam maleate (Roche, Switzerland) plus 25 mg/ml
ketamine hydrochloride (Sigma-Aldrich, Italy). Ani-
mals with patent catheters displayed clear signs of
sedation within 3 s (Caine et al. 1999). Only data from
rats with patent catheter (63/68) were included in the
analysis.
GHB self-administration procedure
One week after surgery, rats were allowed to self-
administer GHB or vehicle for a 2-h session daily (for
7 d/wk) under a FR2 20-s timeout schedule of reinfor-
cement. The self-administration session started with
the introduction of both the active and the inactive
levers : two active lever presses resulted in a 6-s infu-
sion of GHB and a stimulus light above the active lever
came on for 20 s to signal timeout (i.e. when active
lever presses would not result in GHB infusion). In-
active lever presses were recorded but had no pro-
grammed consequences. The eﬀects of vehicle and
0.001, 0.003, 0.01, 0.03, 0.1, 0.3, 3 and 10 mg/kg per
0.1 ml GHB were studied in nine independent groups
of naive rats (each containing 7–8 naive rats). These
doses were chosen on the basis of previous studies
on GHB intravenous self-administration (Beardsley
et al. 1996 ; Fattore et al. 2001 ; Martellotta et al.
1998 ; Woolverton et al. 1999). After 14 d GHB self-
administration, rats underwent a 2-h extinction
session per day, which was identical to the self-
administration session except that GHB was replaced
with sterile saline. Since no diﬀerences in the number
of infusions, active and inactive lever presses were
observed between groups (see Results section) these
extinction sessions were stopped after 7 d.
It has been shown that animals housed under an
inverted light/dark schedule are more active in op-
erant cages and that conducting self-administration
sessions during the dark phase inﬂuences the intake of
several drugs (Caine et al. 1993 ; Finlay et al. 1989).
Therefore, since GHB did not reliably maintain self-
administration when available during the light phase
of the light/dark cycle in a second experiment, GHB
self-administration was evaluated in 18 rats housed
under an inverted 12-h light/dark cycle (lights on
19:30 hours). Rats were allowed to adapt to these
novel conditions for 3 wk before starting a self-
administration procedure. GHB at 0.01 and 0.03 mg/
kg per 0.1 ml was tested since these doses were self-
administered at a higher rate compared to vehicle
when available during the light phase of the light/
dark cycle.
CPP
Apparatus
The in-house-made apparatus consisted of four rec-
tangular boxes (80r40r30 cm) with three sides
made of wood, one long Plexiglas observation wall,
and a wooden lid, as previously described (Cervo &
Samanin, 1995 ; Cervo et al. 1996, 1997, 2002, 2005). For
the conditioning phase, each box was divided into
two equal-sized compartments by a sliding wall : one
compartment was painted grey, and the other black
with vertical white stripes 3 cm wide, whereas the lids
were painted to match the respective compartments.
The two compartments were ﬁtted with distinctive
metal ﬂoors : one with a loose mesh and the other with
a much closer grid.
For pre-conditioning and test sessions, the partition
between the two compartments was raised 12 cm oﬀ
the ﬂoor and a 5r3 cm smooth aluminium platform
was inserted between them. Two infrared sensors
(IMC-S7801-02, Murata Electronics, Japan), one for
each compartment, set to detect any change in the
infrared emission due to a moving body, were as-
sembled on the partition with a relevance angle of 20x,
so that both signalled the rat in the central zone when
it was on the platform or stayed very close to it. The
sensors were operated by a computer that recorded
the time the animal spent in the diﬀerent compart-
ments (by activation of a single sensor), and in the
central zone (activation of both sensors).
The testing room was closed and ventilated, with
dim indirect lighting provided by one 15 W incan-
descent white bulb positioned 50 cm above the boxes.
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A loudspeaker about 1 m above the boxes delivered
white noise.
CPP procedure
As previously described (Cervo et al. 2002, 2005), on
the ﬁrst day, before any drug treatment, each rat was
allowed to explore the apparatus for 15 min, and the
time spent in the two compartments was recorded.
Rats were then assigned to treatment groups and
conditioning compartments, ensuring that all treat-
ments were matched as closely as possible between
compartments.
The schedule during the conditioning phase con-
sisted of oral administration of drug or vehicle on
alternate days. The interval between conditioning days
was no less than 24 h and no more than 72 h, a pro-
cedure that does not inﬂuence CPP in our experimen-
tal conditions (Cervo et al. 2002, 2005).
Thus, on odd conditioning days rats were given
GHB before being conﬁned to the randomly desig-
nated drug side. On the even conditioning days, rats
were treated with vehicle and conﬁned to the opposite
side. This daily order of exposure to drug and vehicle
was counter-balanced for the rats in each group. Con-
trol animals received vehicle in both compartments.
On the test day, neither drug nor vehicle was ad-
ministered. Each rat was placed in the centre of the
aluminium platform separating the two compart-
ments, with free access to both sides of the box, and
the time spent in each compartment was recorded
over a 15-min period. The diﬀerence in time spent in
the drug- and vehicle-associated compartments in the
ﬁnal test session was taken as a measure of place
conditioning.
Evaluation of GHB-induced CPP
To assess whether GHB induced CPP, 30 rats were
assigned to three groups of equal size. Two groups
received 10 conditioning sessions with oral GHB (175
or 350 mg/kg) every other day (see Martellotta et al.
1997) administered 30 min before being conﬁned to
the designated drug side for 30 min. On intervening
days, animals received vehicle and were conﬁned to
the vehicle-designated compartment. The third group
received vehicle in both assigned drug- and vehicle-
associated compartments every day.
Since the aim of our study was to evaluate the eﬀect
of GHB-induced CPP following its injection into lo-
calized brain regions, and in view of the unspeciﬁc
tissue damage that may result from repetitive intra-
cerebral injections, in a second experiment we tried to
decrease the number of conditioning sessions required
to achieve a signiﬁcant CPP by oral GHB. To this end,
we shortened the time between conditioning sessions,
in an attempt to make the association between drug
and compartment more stringent. Because GHB has
a short half-life (Kaufman & Nelson, 1987), we could
reliably perform two conditioning sessions a day, one
with the drug and one with the vehicle. Thus, three
separate groups of 10 naive rats received 350 mg/kg
GHB orally 30 min before being conﬁned to the ran-
domly designated drug side for 30 min. Three diﬀerent
conditioning schedules were examined: 5, 8 and 10
GHB pairings, with rats receiving the vehicle on al-
ternative consecutive pairings. A fourth group of equal
size received vehicle in both the randomly assigned
drug and vehicle compartment on every session.
GHB-elicited CPP could be confounded by its ability
to induce sedation and amnesia (Lobina et al. 2001;
Miotto et al. 2001 ; Schwartz et al. 2000 ; Varela et al.
2004). Therefore, to exclude a possible GHB-induced
state-dependence (Overton, 1978 ; Tzschentke, 2007;
Weingartner et al. 1978), four groups of rats under-
went ﬁve conditioning sessions twice daily with oral
350 mg/kg GHB or vehicle as described above, but
were tested 30 min after being treated with oral GHB
(350 mg/kg) or vehicle.
GHB application in VTA and NAc
GHB was bilaterally injected in the VTA (0, 10, 30, 100,
300 mg/0.5 ml per side) or in the NAc (0, 10, 30, 100 mg/
0.5 ml per side) in two groups of 40 and 32 rats, re-
spectively. Animals were deeply anaesthetized with
equitesin and placed in a Kopf stereotaxic frame (Kopf,
USA). Guide cannulae made of 23-gauge stainless-
steel tubing were secured by acrylic dental cement
anchored to three stainless-steel screws ﬁxed to the
skull. To prevent clogging, 30-gauge stainless steel
stylets were placed in the guide cannulae until the
animals were given local GHB infusions.
During the 1-wk recovery, rats received an ampi-
cillin injection (45 mg/kg s.c.) daily for the ﬁrst 5 d
and were handled every day. For drug infusion, the
stylets were withdrawn and replaced by injection
needles (30-gauge stainless-steel tubing) terminating
2 mm below the tip of the guides. Stereotaxic co-
ordinates for the VTA and NAc cannulae were
x6.7 mm AP,¡0.8 mm L,x8.4 mmH, and+2.2 mm
AP, ¡1.4 mm L, x7.0 mm H, respectively (from
bregma) (Paxinos & Watson, 1998). Injections were
made using an infusion pump (Harvard Instruments,
USA).
After the 15-min preconditioning stage, rats re-
ceived ﬁve conditioning pairings, each consisting of
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30-min exposures to two distinct compartments of the
CPP chambers. Two conditioning sessions per day
were conducted during the light phase of the light/
dark cycle : one in the early morning, and one in the
afternoon. The injection needle was attached to the
pump syringe by polythene tubing ﬁlled with either
drug or vehicle. The volume of each local infusion was
0.5 ml over 30 s, and the injection needles were left in-
side the guide cannulae for 1 min before being with-
drawn to allow diﬀusion from the tip and to prevent
reﬂux of the solution.
The rats were then immediately placed into the
randomly assigned drug compartment for 30 min. In
the afternoon, animals received a sham local injection
using an identical procedure as described above, ex-
cept that the injection cannulae were disconnected
from the infusion pump. The injection needle was the
same length as the guide cannulae, so the tissue was
preserved from mechanical damage. This procedure
was utilized instead of a saline infusion to minimize
potential damage that might result from repeated local
infusions (Baker et al. 1998). The drug-designated com-
partment and the order of treatment (vehicle/drug vs.
sham local injection) were counter-balanced across
groups. On the day following the last conditioning
session, animals were tested for CPP. At the end of
the experiments, rats were deeply anaesthetized with
200 mg/kg pentobarbital and killed by decapitation.
Cannula placements were veriﬁed in Cresyl Violet-
stained sections, and data from two NAc-implanted
and four VTA-implanted rats were discarded because
of non-optimal cannula placement.
Drugs
The doses of GHB (CT Laboratories, Italy) are ex-
pressed as sodium salt. For self-administration, GHB
was dissolved in sterile saline to produce a stock sol-
ution of 100 mg/ml. This stock solution was further
diluted with sterile saline to produce the appropriate
concentration of GHB (mg/kg per 0.1 ml infusion),
adjusted for each rat according to body weight. For
local injections, GHB was dissolved in sterile saline.
Drug solutions were prepared in a laminar airﬂow
cabinet and ﬁltered through a 22-mm syringe ﬁlter. For
oral administration, GHB was dissolved in sterile
water and given by a gavage in a volume of 2 ml/kg.
All solutions were freshly prepared immediately be-
fore use.
Statistical analysis
The number of infusions, active and inactive lever
presses earned during the self-administration and the
extinction sessions were analysed by mixed factorial
analysis of variance (ANOVA), with GHB doses as
between factor and sessions as within factor. Post-hoc
comparisons were made by Newman–Keuls (NK) test.
The mean number of infusions earned during the 14 d
GHB self-administration in diﬀerent light/dark cycle
conditions was compared by two-way ANOVA, with
light/dark phase and GHB dose as main factors, fol-
lowed by NK test.
In the CPP experiments, to exclude any uncon-
ditioned preference for one or the other side of the
apparatus, we compared the time spent by rats in the
black/white and grey compartments during the pre-
conditioning session using paired Student’s t test.
One-way ANOVA followed by Dunnett’s test com-
paring the diﬀerence in time spent in the drug-paired
and the vehicle-associated compartments in the ﬁnal
test session (i.e. preference for drug-associated side)
was used to assess the eﬀects of GHB when adminis-
tered alone. The two-way ANOVA followed by NK
post-hoc comparison was used to evaluate diﬀerences
in preference for drug-associated side when the num-
ber of GHB conditioning sessions was varied. The
eﬀect of GHB given during the test session on GHB-
induced CPP was analysed by two-way ANOVA
followed by NK test. The same tests were used to de-
termine any change induced by the diﬀerent treat-
ments on the time the animals spent in the central zone
of the CPP apparatus.
Results
GHB and self-administration
The mixed factorial one-way ANOVA found a sig-
niﬁcant eﬀect of GHB on the number of infusions
and active lever presses but not on the inactive
lever presses [infusions : FGHB(8, 54)=5.5, p<0.05 ;
Fsessions(13, 104)=38.6, p<0.05; FGHBrsessions(104, 702)=
2.5, p>0.05 ; active lever presses : FGHB(8, 54)=
4.8, p<0.05 ; Fsessions(13, 104)=71.7, p<0.05 ;
FGHBrsessions(104, 702)=2.2, p>0.05). Post-hoc com-
parisons (NK test) revealed that only 0.01 mg/kg per
infusion maintained GHB self-administration, al-
though not on every test day. In particular, a sig-
niﬁcant increase in the number of infusion (Fig. 1a)
and active lever presses (data not shown) was found
on days 1, 2, 4, 8, 9, 10 and 13 (p<0.05 compared to
vehicle), but not on days 3, 5, 6, 7, 11, 12 and 14.
To visualize the entire dose–response curve, Fig. 1b
illustrates the mean number of diﬀerent GHB doses
and as infusions during the 14 d self-administration,
while the numbers of active and inactive lever
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presses are depicted in Fig. 1c. Post-hoc comparisons
also revealed that a lower number of 3 and 10 mg/
kg per infusion GHB was earned on day 1 (data not
shown) (p<0.05 compared to vehicle). Moreover, no
signiﬁcant diﬀerences in the number of infusions
(see Fig. 1a) and active and inactive lever presses
(data not shown) was found during the extinction
sessions.
Figure 1d shows the eﬀect of 0.01 and 0.03 mg/
kg per infusion GHB when available for self-
administration during the dark period of the light/
dark cycle. Two-way ANOVA found a signiﬁcant
eﬀect of the light/dark phase [F(1, 30)=12.0, p<0.05]
and of GHB [F(2, 30)=4.4, p<0.05]. Post-hoc compari-
sons (NK test) revealed that during the light phase
rats earned more infusions of 0.01 but not 0.03 mg/kg
per infusion compared to vehicle (p<0.05) and com-
pared to rats self-administering the same dose during
the dark phase (p<0.05). No diﬀerence between the
number of GHB and vehicle infusions was observed
during the dark phase of the light/dark cycle. More-
over, no changes in the number of infusions, and of
active or inactive lever presses were observed during
the period of extinction (data not shown).
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Fig. 1. Gamma-hydroxybutyric acid (GHB) self administration. (a) The mean number of 0.01 mg/kg per infusion earned under
FR2 20-s timeout in daily 2 h self-administration sessions and during extinction are illustrated. (b) The mean (¡S.E.M.) number
of GHB infusions earned in the 14 d self-administration. For comparison, the mean (¡S.E.M.) number of active and inactive
lever presses performed in the 14 d self-administration is shown in panel (c). (d) The mean (¡S.E.M.) number of GHB infusions
( ) earned during the 14 d self-administration during the light or the dark phases of the light/dark cycle compared to vehicle
(&). Data in panel (a) were analysed by mixed factorial ANOVA (with GHB dose as between factor and sessions as within
factor), whereas data in panel (d) were analysed by two-way ANOVA (with light/dark phase and GHB dose as main
factors). Post-hoc comparisons were made by NK test. (See text for further details.) * p<0.05 vs. vehicle ; # p<0.05 vs. 0.01 mg
dark phase.
148 J. Watson et al.
Overall, therefore, these data indicate that GHB
is unable to reliably maintain intravenous self-
administration in naive food-restricted rats, when it
is available under a FR2 20-s timeout schedule.
GHB and CPP
No diﬀerence was found in the unconditioned pref-
erence for grey or black/white compartment (385.3¡
3.7 s or 390.8¡4.1 s, n=188, respectively ; p>0.05,
paired Student’s t test). Moreover in all experiments,
the animals spent from 97.5¡7.6 to 146.0¡28.4 s in the
central zone of the CPP apparatus, and no diﬀerence
could be detected for the various experimental groups
(p>0.05, Dunnett’s or NK test). Thus, the preference
for the GHB-paired side in the diﬀerent experiments
reported below was not signiﬁcantly inﬂuenced by
changes in time spent in the central zone.
Figure 2a shows the eﬀects of 10 conditioning
sessions with 175 and 350 mg/kg GHB given orally.
One-way ANOVA indicated a signiﬁcant eﬀect of
treatment [F(2, 27)=6.6, p<0.05]. Post-hoc compari-
sons demonstrated that 350 mg/kg GHB, but not
175 mg/kg, induced a clear CPP, with treated animals
spending more time in the drug-associated compart-
ment (p<0.05 vs. control group, Dunnett’s test).
Figure 2b shows the place conditioning induced
by 5, 8 and 10 daily pairings with 350 mg/kg GHB
given orally, with these rats receiving the vehicle on
alternative consecutive pairings. A signiﬁcant eﬀect of
treatment [F(1, 54)=34.1, p<0.05] but not of sessions
was found. Post-hoc analyses revealed that indepen-
dently from the number of conditioning sessions rats
spent more time in the GHB-associated compartment
(p<0.05 vs. respective control group, NK test) for both
5, 8 and 10 pairings.
As shown in Fig. 2c, the CPP induced by ﬁve pair-
ings with oral 350 mg/kg GHB was found regard-
less of whether testing was carried out in the drugged
or un-drugged state (p<0.05 vs. respective vehicle-
treated group, NK test), thus excluding potential
state-dependent eﬀects as an explanation of the GHB-
induced CPP [Fcond(1, 28)=11.6, p<0.05 ; Ftest(1, 28)=
3.0, p>0.05 ; Fcondrtest(1, 28)=0.1, p>0.05, two-way
ANOVA].
The eﬀect on CPP of GHB locally applied in the
VTA or the NAc is reported in Fig. 3. Five injections of
GHB into the VTA but not into the NAc induced a sig-
niﬁcant CPP [FVTA(3, 26)=4.5, p<0.05 ; FNAc(3, 26)=
0.3 ; p>0.05, one-way ANOVA]. Post-hoc comparisons
indicated that VTA-injected 30 and 100 mg GHB,
but not 10 and 300 mg, induced a signiﬁcant CPP
with treated animals spending more time in the drug-
associated compartment (p<0.05 compared to vehicle-
treated group, Dunnett’s test).
Discussion
The main ﬁnding of this study is that GHB induces
CPP when injected directly into the VTA but not in the
NAc, demonstrating that the former but not the latter
brain area is likely to represent one of the primary sites
of action for the rewarding properties of this drug.
Moreover, our study is the ﬁrst to demonstrate that the
GHB-elicited CPP is not inﬂuenced by GHB-induced
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state-dependence, since CPP could be observed in ani-
mals that were both in a ‘drugged’ and ‘undrugged’
condition.
The dopaminergic VTA neurons project to basal
forebrain structures, such as the NAc, amygdala, and
frontal and limbic cortex (Camı´ & Farre´, 2003 ; Gardner
& Lowinson, 1993 ; Maldonado, 2003). Activation of
VTA neurons, together with the resulting increase in
dopamine output in the innervated structures, has
been suggested to mediate the rewarding properties
of drugs of abuse (Koob et al. 1998 ; Robbins & Everitt,
1999 ; Wise & Bozarth, 1987). The remaining VTA neu-
rons are mainly GABAergic and function either as
local interneurons to modulate the activity of the dop-
aminergic cells or as projection neurons providing an
inhibitory input to the cortex and the NAc (Carr &
Sesack, 2000 ; Kalivas, 1993). With respect to mech-
anisms of GHB action, in-vitro evidence has dem-
onstrated bi-directional eﬀects of GABAB receptor
activation on the VTA output. Cruz et al. (2004), and
more recently Laboue`be et al. (2007) showed that,
owing to diﬀerences in distribution of inwardly rectify-
ing K+ channel subunits, GABAB receptor agonists hy-
perpolarize GABAergic neurons with a smaller ED50
than dopaminergic neurons. Thus, these authors hypo-
thesized that at doses typically used during its rec-
reational use GHB would preferentially inhibit VTA
GABAergic neurons, with a resulting disinhibition
of dopaminergic neurons, leading to an increased VTA
output that would underlie GHB’s rewarding proper-
ties. With higher GHB doses leading to higher brain
concentrations, the VTA dopaminergic neurons would
also be directly hyperpolarized, with a resulting de-
crease in VTA output, which may explain the ben-
eﬁcial properties of GHB in alcoholics (Addolorato
et al. 1999 ; Caputo et al. 2005 ; Gallimberti et al. 1989;
Nava et al. 2007) and our ﬁnding of its inability to in-
duce CPP when injected at higher concentrations in
this brain region. This scenario is also supported by
the ﬁnding that intravenous administration of rela-
tively high doses of GHB either depresses or increases
ﬁring of VTA dopaminergic neurons with a high or
low baseline ﬁring rate, respectively (Pistis et al. 2005).
Finally, the lack of GHB action in the NAc supports the
speciﬁcity of the eﬀects we observed when injected in
the VTA, and would exclude a direct involvement
of the NAc in the rewarding properties of this drug
when administered orally or systemically. However,
because of the GABAergic projections from the VTA to
the cortex (Carr & Sesack, 2000) and the NAc (Van
Bockstaele & Pickel, 1995), an indirect involvement of
the latter two brain regions to the rewarding action
of GHB cannot be excluded (Johnson & North, 1992;
Kalivas, 1993).
Another major result of our study is that GHB is
only a weak reinforcer when evaluated in intravenous
self-administration, both during the light and the dark
phases of the light/dark cycle, with only 0.01 mg/kg
per infusion GHB being self-administered at higher
frequency compared to vehicle, and not at each evalu-
ated day. Moreover, when available at the highest
doses (3 and 10 mg/kg per infusion) GHB reduced the
number of infusions compared to vehicle, at least dur-
ing the ﬁrst day of self-administration, suggesting a
potential sedative or aversive activity of this drug, as
hypothesized in monkeys (Woolverton et al. 1999). The
fact that no extinction was observed when GHB was
substituted with vehicle (at least in animals that self-
administered 0.01 mg/kg per infusion GHB), together
with the inability of this drug to be self-administered
during the dark phase of the light/dark cycle, support
our conclusion of a weak reinforcing property of GHB
as evaluated in this behavioural procedure.
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Nevertheless, caution should be used in interpreting
potentially contradictory results, since it is impossible
to demonstrate that a drug will not produce CPP or
be self-administered under any condition at diﬀerent
doses in various species. Indeed, although the lack of a
consistent self-administration of intravenous GHB in
our study agrees with previous results in monkeys
(Beardsley et al. 1996 ; Woolverton et al. 1999), it has
also been reported that GHB is intravenously self-
administered by mice (Fattore et al. 2001 ; Martellotta
et al. 1998). However, the methodology between these
studies and our study diﬀers greatly. Whereas we
investigated the ability of GHB to maintain self-
administration, Martellotta et al. (1998) and Fattore et
al. (2001) studied only acute GHB self-administration,
i.e. each mouse underwent only one self-administra-
tion session. In our experiments, rats indeed self-
administered GHB more than vehicle during the ﬁrst
sessions (at least at 0.01 mg/kg per infusion), but this
does not necessarily mean that the compound was
maintaining a self-administration behaviour, as in-
dicated by the fact that in the subsequent 13 d there
was no overall higher infusion rate of GHB compared
to vehicle. Moreover, no extinction was evident after
replacing GHB with vehicle. All these ﬁndings, there-
fore, indicate that in rats, under the conditions used
in our study, GHB is, at most, a weak reinforcer. How-
ever, it cannot be excluded that diﬀerent conditions,
i.e. longer sessions and/or time out, could bring about
a more robust self-administration.
In humans, GHB is self-administered orally. Oral
self-administration of GHB, in preference to water,
has been observed in rats (Colombo et al. 1995), al-
though periods of voluntary abstinence were seen
during the tests and the self-administration was often
irregular. In a recent study, GHB was also orally self-
administered by mice (Laboue`be et al. 2007), although
comparison with other studies is diﬃcult due to the
paucity of information on preconditioning and test
procedures. Thus, the reasons for the diﬀerent eﬀects
observed when GHB is given orally or made available
as intravenous infusion in operant self-administration
are at present unclear, although diﬀerence in metab-
olism, speed of brain penetration, cerebral distribution
and/or modality of drug availability may account for
the reported diﬀerences.
In conclusion, our results demonstrate for the ﬁrst
time that GHB injected directly into the VTA can be
rewarding in naive rats. Together with recent in-vitro
ﬁndings (Cruz et al. 2004 ; Laboue`be et al. 2007), these
data suggest that the rewarding properties of GHB
mainly occur via disinhibition of VTA dopaminergic
neurons.
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